Eden Wells, Novartis chief insights and decision science officer, at the Financial Times' US Pharma and Biotech Summit, held in partnership with Endpoints News (Sarah Merians Photography for Endpoints News)
May 16, 2024 03:18 PM EDT
Pharma
Health Tech

Phar­ma is re­think­ing how it in­ter­acts with pa­tients af­ter Eli Lil­ly ripped up the play­book

Shelby Livingston

Senior health tech reporter

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)

More phar­ma com­pa­nies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times